
    
      The multicenter randomized phase II study will enroll a target of approximately 150
      first-line patients with metastatic CRC.

      EGFR expression is not required for study entry, however, the EGFR status will be measured
      retrospectively.

      Patients are randomized to Arm A or Arm B. Arm A: FOLFOX 6 in combination with cetuximab Arm
      B: FOLFIRI in combination with cetuximab. Both efficacy and safety data will be collected.
      The investigators will assess response to treatment at 6 weeks, 12 weeks and thereafter every
      12 weeks based on imaging Following permanent treatment cessation (stop of all study
      treatments) patients will be followed-up for.
    
  